PLIVA Completes Divestment of Research Institute
PLIVA d.d. announced that it has completed the divestment of PLIVA - Istrazivaki Institut d.o.o. (PLIVA - Research Institute Ltd.), PLIVA's proprietary R&D arm to GlaxoSmithKline (GSK).
PLIVA received a payment of USD 35m upon closing of the transaction and is entitled to contingent payments totaling up to USD 15m conditional on the entry of certain early stage projects into clinical development. In addition, PLIVA will receive contingent royalty-based consideration pending commercialisation of certain assets.
The closing of the transaction will positively impact PLIVA Group results by an exceptional gain on sale of the discontinued business of about USD 20m in the second quarter 2006. Ongoing financing of the discontinued proprietary R&D operations through to closing will also impact PLIVA Group results by about USD 6m. Both items will be recorded below the operating line (EBIT).
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.